Technology area: Biotechnology & Pharmaceuticals
20 pending office actions • 16 clients • 20 examiners • 15 art units • 0 of 20 (0%) have an AI response strategy ready
Baker, Donelson, Bearman, Caldwell & Berkowitz, PC has 19 pending office actions in Biotechnology & Pharmaceuticals, against 2,415 career applications. Its resolved allowance rate is 86.46%, providing a direct measure of outcomes across that application base. The profile therefore combines a relatively limited current action docket with a broader historical record in the same technology area.
The average is 3.15 office actions per allowance. That figure indicates that allowed matters have generally required multiple prosecution exchanges, rather than progressing through allowance after a single action. For practitioners, the combination of 86.46% resolved allowance and 3.15 actions per allowance supports planning for continued examination work while preserving a meaningful allowance objective. The pending docket should be reviewed separately from the career application history when assessing current workload.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (10%) |
| §103 only | 1 (5%) |
| §112 only | 2 (10%) |
| Double-patenting + other | 3 (15%) |
| Multi-statute (no §101) | 10 (50%) |
| No statute on record | 2 (10%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WEDDINGTON, KEVIN E | 1 | 75.3% | +9.8% |
| PERRIN, CLARE M | 1 | 68.3% | +42.6% |
| JARRELL, NOBLE E | 1 | 80.9% | +10.0% |
| PERSONS, JENNA L | 1 | 50.8% | +61.7% |
| BANERJEE, KOYELI | 1 | 33.3% | +0.0% |
| PAK, MICHAEL D | 1 | 58.6% | +29.9% |
| O DELL, DAVID K | 1 | 57.7% | +36.0% |
| CHERNYSHEV, OLGA N | 1 | 54.5% | +34.0% |
| JOHNSON, TIRONE DEREK | 1 | 0.0% | +0.0% |
| SHIN, DANA H | 1 | 26.9% | +26.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18695384 | POLYCYCLIC FUSED RING DERIVATIVES AND USE THEREOF | JARRELL, NOBLE E | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18029400 | EGFR-TARGETING CHIMERIC ANTIGEN RECEPTOR | AEDER, SEAN E | 22d |
| 18722120 | ANTIMICROBIAL SYSTEM AND METHOD | PERRIN, CLARE M | — |
| 18695012 | Aptamer for DKK1 and Use Thereof | PERSONS, JENNA L | — |
| 18586899 | GIP RECEPTOR AGONIST AND USE THEREOF | BANERJEE, KOYELI | — |
| 18683790 | TREATMENT OF CLUSTER HEADACHE USING ANTI-CGRP ANTIBODIES | PAK, MICHAEL D | — |
| 18561909 | Compound containing phosphate group, pharmaceutical composition containing same, preparation method therefor and use thereof | O DELL, DAVID K | — |
| 18561018 | Improved immunoglobulin I | JOHNSON, TIRONE DEREK | — |
| 18283468 | NUCLEIC ACID MOLECULE CONJUGATE HAVING PROLONGED IN VIVO HALF-LIFE | SHIN, DANA H | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18722120 | ANTIMICROBIAL SYSTEM AND METHOD | PERRIN, CLARE M | — |
| 18695384 | POLYCYCLIC FUSED RING DERIVATIVES AND USE THEREOF | JARRELL, NOBLE E | — |
| 18695012 | Aptamer for DKK1 and Use Thereof | PERSONS, JENNA L | — |
| 18683790 | TREATMENT OF CLUSTER HEADACHE USING ANTI-CGRP ANTIBODIES | PAK, MICHAEL D | — |
| 18561909 | Compound containing phosphate group, pharmaceutical composition containing same, preparation method therefor and use thereof | O DELL, DAVID K | — |
| 18511241 | TREATMENT OF MEDICATION OVERUSE HEADACHE USING ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES | CHERNYSHEV, OLGA N | — |
| 18283468 | NUCLEIC ACID MOLECULE CONJUGATE HAVING PROLONGED IN VIVO HALF-LIFE | SHIN, DANA H | — |
| Art Unit | Apps |
|---|---|
| 1621 | 2 |
| 1644 | 2 |
| 1642 | 2 |
| 1789 | 2 |
| 1629 | 1 |
| 1779 | 1 |
| 1699 | 1 |
| 1637 | 1 |
| 1658 | 1 |
| 1675 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18818701 | TRICYCLIC COMPOUNDS | Jacobio Pharmaceuticals Co., Ltd. | WEDDINGTON, KEVIN E | 1629 | Other | Non-Final OA | — | Pending | Aug 29, 2024 |
| 18722120 | ANTIMICROBIAL SYSTEM AND METHOD | Kemira Oyj | PERRIN, CLARE M | 1779 | §103§112 | Non-Final OA | — | Pending | Jun 20, 2024 |
| 18695384 | POLYCYCLIC FUSED RING DERIVATIVES AND USE THEREOF | Jacobio Pharmaceuticals Co., Ltd. | JARRELL, NOBLE E | 1699 | §112 | Non-Final OA | — | Pending | Mar 26, 2024 |
| 18695012 | Aptamer for DKK1 and Use Thereof | Aptacure Therapeutics Limited | PERSONS, JENNA L | 1637 | §102§112 | Non-Final OA | — | Pending | Mar 25, 2024 |
| 18586899 | GIP RECEPTOR AGONIST AND USE THEREOF | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | BANERJEE, KOYELI | 1658 | §103§112 | Non-Final OA | — | Pending | Feb 26, 2024 |
| 18683790 | TREATMENT OF CLUSTER HEADACHE USING ANTI-CGRP ANTIBODIES | H. Lundbeck A/S | PAK, MICHAEL D | §103§112 | Non-Final OA | — | Pending | Feb 15, 2024 | |
| 18561909 | Compound containing phosphate group, pharmaceutical composition containing same, preparation method therefor and use thereof | Shanghai Raising Pharmaceutical Co., Ltd. | O DELL, DAVID K | 1621 | §101§102§103§112DP | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18511241 | TREATMENT OF MEDICATION OVERUSE HEADACHE USING ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES | H. Lundbeck A/S | CHERNYSHEV, OLGA N | 1675 | Other | Final Rejection | — | Pending | Nov 16, 2023 |
| 18561018 | Improved immunoglobulin I | Transmab Pty Ltd. | JOHNSON, TIRONE DEREK | 1618 | §103§112 | Non-Final OA | — | Pending | Nov 15, 2023 |
| 18283468 | NUCLEIC ACID MOLECULE CONJUGATE HAVING PROLONGED IN VIVO HALF-LIFE | Aptacure Therapeutics Limited | SHIN, DANA H | 1635 | §103§112DP | Non-Final OA | — | Pending | Oct 25, 2023 |
| 18283834 | NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | Jacobio Pharmaceuticals Co., Ltd. | RODRIGUEZ-GARCIA, VALERIE | 1621 | §112 | Non-Final OA | 60d | Pending | Sep 25, 2023 |
| 18278646 | VILLI STROMAL CELLS COMPOSITIONS AND USES THEREOF | Arugula Sciences LLC | TICHY, JENNIFER M.H. | 1653 | §102§112 | Non-Final OA | — | Pending | Aug 24, 2023 |
| 18271106 | NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOF | Immunext, Inc. | CHANDRAKUMAR, NIZAL S | 1625 | §103§112 | Non-Final OA | — | Pending | Jul 06, 2023 |
| 18317498 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | Janssen Pharmaceuticals, Inc. | OUSPENSKI, ILIA I | 1644 | §112DP | Non-Final OA | — | Pending | May 15, 2023 |
| 18029400 | EGFR-TARGETING CHIMERIC ANTIGEN RECEPTOR | BEIJING INSTITUTE FOR STEM CELL AND REGENERATIVE MEDICINE | AEDER, SEAN E | 1642 | §102§103 | Non-Final OA | 22d | Pending | May 04, 2023 |
| 18125762 | REDUCING FRATRICIDE OF IMMUNE CELLS EXPRESSING NKG2D-BASED RECEPTORS | Celyad S.A. | MOSELEY II, NELSON B | 1642 | §112DP | Final Rejection | 28d | Pending | Mar 24, 2023 |
| 18064514 | CHIMERIC ANTIGEN RECEPTORS TARGETING TIM-1 | Celldex Therapeurics, Inc. | SKELDING, ZACHARY S | 1644 | §102§103§112 | Non-Final OA | — | Pending | Dec 12, 2022 |
| 17923264 | DIRECTED EVOLUTION METHOD BASED ON PRIMARY AND SECONDARY REPLICON OF GEMINI VIRUS | Suzhou Qi Biodesign Biotechnology Company Limited | PARISI, JESSICA DANIELLE | 1684 | §101§102§103§112 | Final Rejection | — | Pending | Nov 04, 2022 |
| 17769779 | POLYAMIDE SEA-ISLAND FIBER, PREPARATION METHOD THEREFOR, AND USE THEREOF | Cathay (Wusu) Biomaterial Co., Ltd. | JOHNSON, JENNA LEIGH | 1789 | §103§112 | Final Rejection | — | Pending | Apr 18, 2022 |
| 17637093 | POLYAMIDE 56 FIBRE WITH LOW BOILING WATER SHRINKAGE RATE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Cibt America Inc. | PIZIALI, ANDREW T | 1789 | §103 | Final Rejection | — | Pending | Feb 22, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial86.5% of resolved applications prosecuted by Baker, Donelson, Bearman, Caldwell & Berkowitz, P.C. were allowed, across 2,415 applications in USPTO records.
3.15 office actions per allowed application on average.
20 pending office actions as of October 2026, for 16 clients, before 20 examiners in 15 art units.
